Do you want to skip to content? Skip to content
Contact Us Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本
Convatec Contact Us Argentina Argentina Belize Belize Brasil Brasil Canada (English) Canada (English) Canada (Français) Canada (Français) Chile Chile Colombia Colombia Costa Rica Costa Rica Curaçao Curaçao El Salvador El Salvador Ecuador Ecuador Guatemala Guatemala Guyana Guyana Honduras Honduras Jamaica Jamaica México México Nicaragua Nicaragua Panamá Panamá Perú Perú Puerto Rico Puerto Rico República Dominicana República Dominicana Suriname Suriname Venezuela Venezuela United States (English) United States (English) België België Bosna i Hercegovina Bosna i Hercegovina Česko Česko Danmark Danmark Deutschland Deutschland Eesti Eesti España España France France Hrvatska Hrvatska Ireland Ireland Ísland Ísland Italia Italia Latvija Latvija Lietuva Lietuva Magyarország Magyarország Malta Malta Nederland Nederland Norge Norge Polska Polska Portugal Portugal România România Schweiz (Deutsch) Schweiz (Deutsch) Suisse (Français) Suisse (Français) Slovenija Slovenija Slovensko Slovensko Srbija Srbija Suomi Suomi Sverige Sverige Türkiye Türkiye United Kingdom United Kingdom Österreich Österreich Ελλάδα Ελλάδα България България Македонија Македонија Россия Россия Україна Україна South-Africa South-Africa ישראל ישראל الأردن الأردن الإمارات العربية المتحدة الإمارات العربية المتحدة البحرين البحرين المملكة العربية السعودية المملكة العربية السعودية ایران ایران پاکستان پاکستان عُمان عُمان قطر قطر لبنان لبنان مصر مصر العراق العراق الكويت الكويت Australia Australia Hong Kong SAR Hong Kong SAR 中国香港 中国香港 India India Indonesia Indonesia Malaysia Malaysia New Zealand New Zealand Philippines Philippines Singapore Singapore Việt Nam Việt Nam ไทย ไทย 대한민국 대한민국 中国 中国 中国台湾 中国台湾 日本 日本

Convatec will be launching in Europe Chlorasolv, a gentle wound debrider efficient against biofilm, within the recognized Wound HygieneTM protocol of care, designed to accelerate healing in hard-to-heal wounds. 


Convatec, one of the world’s leading companies in advanced wound care and RLS Global, a medical healthcare company based in Sweden, have entered a global collaboration to commercialize ChloraSolv. ChloraSolv is a ground-breaking gentle debrider, which is already currently sold in some European countries. ChloraSolv will be included in Convatec’s Wound Hygiene
TM Protocol of care for hard-to-heal wounds, which was developed by Key Opinion Leaders (“KOLs”) and promoted by Convatec, where it will add a significant benefit in terms of debridement solutions.

The collaboration includes rights to commercialize ChloraSolv in Europe with immediate effect, and future rights to commercialize in the USA and Rest of World (“ROW”) upon regulatory approval. Within the framework of the collaboration, Convatec will leverage its strong global presence and well-established best in class commercial infrastructure to support the commercialization and go-to-market activities for ChloraSolv. RLS will be responsible for continued research and development and Convatec will take the lead for go-to-market activities for ChloraSolv.

“For the past six months, Convatec has thoroughly evaluated the product ChloraSolv and RLS. We concluded that ChloraSolv, with its unique properties, will be an important addition to Convatec’s Wound HygieneTM offering to customers. Gentle yet effective wound debridement is an important component to safe and effective wound healing, and it is critical that more patients have access to this treatment in the future. RLS has an experienced team on board, with impressive knowledge of the advanced wound care business, and has built a very clear and comprehensive roadmap to bring this product to the market. We look forward to establishing a long-term collaboration with RLS”, commented David Shepherd, President & COO, AWC.

 “This collaboration is a breakthrough for RLS and aligned with our vision of being a leading research driven platform company. We are pleased to establish this collaboration with one of the world’s largest wound care companies and that RLS now has access to a comprehensive global distribution channel supported by a committed and competent partner. RLS and Convatec share a common view of ChloraSolv’s patient benefits and its contribution to more cost-effective wound care”, says Karin Fischer – CEO of RLS.

 

ABOUT CONVATEC

Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about Convatec, please visit  www.convatecgroup.com

 

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email:  certifiedadviser@redeye.se. Read more at  www.rls.global

 

CONTACT INFORMATION:
Sandrine Letellier, Vice President Global Marketing Advanced Wound Care, Convatec Ltd, email:  Sandrine.letellier@convatec.com

Press Release

3/5/2022

3/5/2022

Annual Results for the twelve months ended 31 December 2020

Annual Results for the twelve months ended 31 December 2020

3/31/2021

3/31/2021

Convatec awarded contract for Ostomy Products from Vizient, Inc.

Convatec awarded contract for Ostomy Products from Vizient, Inc.

4/29/2021

4/29/2021

Trading update for the three months ended 31 March 2021

Trading update for the three months ended 31 March 2021

6/21/2021

6/21/2021

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS

Global commercial rights signed by Convatec Ltd for ChloraSolv, innovative wound debrider from RLS

7/30/2021

7/30/2021

Interim Results for the six months ended 30 June 2021

Interim Results for the six months ended 30 June 2021

9/30/2021

9/30/2021

Convatec Group Plc Announces Offering of $500 Million Senior Notes due 2029

Convatec Group Plc Announces Offering of $500 Million Senior Notes due 2029

10/1/2021

10/1/2021

Convatec Group Plc Announces Pricing of $500 Million 3.875% Senior Notes due 2029

Convatec Group Plc Announces Pricing of $500 Million 3.875% Senior Notes due 2029

5/13/2022

5/13/2022

Trading update for the three months ended 30 September 2021

Trading update for the three months ended 30 September 2021

5/13/2022

5/13/2022

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

Convatec awarded contract for Advanced Wound Care Products from Vizient, Inc.

5/13/2022

5/13/2022

25 years of AQUACEL

25 years of AQUACEL

5/13/2022

5/13/2022

Chief Financial Officer succession

Chief Financial Officer succession